临床病理参数用于排除BRCA1/2突变携带者作为部分乳腺照射候选者的效用
本研究从单机构2006至2023年连续收治的BRCA1/2致病性变异携带者乳腺癌患者中提取资料,分析282例诊断时遗传状态未知的患者共294个肿瘤。依据ASTRO、ESTRO-IORT、ACROP-ESTRO及GEC-ESTRO等国际指南的临床病理标准,3%至18%的携带者肿瘤符合部分乳腺照射条件。作者建议在高危人群中遵循更严格的指南。
要点
- 按ASTRO指南(不含条件性推荐标准),294个肿瘤中17个(5.8%)符合PBI条件。
- 按ESTRO-IORT及ACROP-ESTRO PBI标准,294个中9个(3%)符合条件。
- 按GEC-ESTRO低危标准294个中31个(10.5%)符合,加入中危标准后总符合率18.7%。
核心结论
- 依据国际指南发表的临床病理标准,3%至18%的BRCA1/2致病性变异携带者肿瘤符合部分乳腺照射条件。
- 作者建议,尤其在BRCA1/2致病性变异携带高危人群中,遵循更严格的指南。
- 在本队列中,ASTRO、ESTRO-IORT和ESTRO PBI标准识别BRCA1/2致病性变异携带者符合PBI的概率最低。
研究设计与样本
- 单机构2006年至2023年连续收治的BRCA1/2致病性变异携带者乳腺癌患者病历资料的提取分析。
- 共分析498例患者518个原发肿瘤,其中282例(含12例同时性双侧病变)诊断时遗传状态未知,构成研究队列,对应294个肿瘤。
- 诊断时中位年龄42.7岁(范围23.8至77.9岁)。
主要发现
- 按近期ASTRO指南(不含条件性推荐标准),294个肿瘤中17个(5.8%)符合PBI条件,包括3个Her2阳性肿瘤和5例年龄40至49岁诊断的患者。
- 按ESTRO IORT及ACROP-ESTRO PBI标准,294个中9个(3%)符合条件。
- 按GEC-ESTRO低危标准,294个中31个(10.5%)符合条件;其中危标准使PBI符合率额外增加8.2%(总体18.7%)。
关键数值与推荐
- ASTRO指南:294个肿瘤中17个(5.8%)符合PBI条件(不含条件性推荐标准)。
- ESTRO IORT及ACROP-ESTRO PBI标准:294个中9个(3%)符合条件。
- GEC-ESTRO低危标准:294个中31个(10.5%)符合条件;加入中危标准后总体符合率18.7%。
临床怎么用
- 作者建议,尤其在BRCA1/2致病性变异携带高危人群中,遵循更严格的指南。
- 在本队列中,ASTRO、ESTRO-IORT和ESTRO PBI标准识别BRCA1/2致病性变异携带者符合PBI的概率最低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several international groups have published guidelines to identify low-risk breast cancer (BC) patients who are eligible for partial breast irradiation (PBI). These include the American Society for Radiation Oncology (ASTRO), the European Society for Radiotherapy and Oncology (ESTRO), and ESTRO subgroups such as the Intraoperative radiation (IORT) Task Force and Groupe Européen de Curiethérapie (GEC) -ESTRO. Only ASTRO guidelines recommend against the use of PBI in known carriers of germline pathogenic variants (PVs) in BRCA1/2. The aim of this study was to evaluate the proportion of BC patients, subsequently found to be BRCA1/2 PV carriers who would be eligible for PBI based on clinical-pathologic criteria of the above-mentioned international guidelines. METHODS AND MATERIALS: Data were extracted from the medical records of consecutive BC BRCA1/2 PV carriers treated at a single institution between 2006 and 2023. Data included patient demographics, tumor characteristics, treatment, and disease outcomes. RESULTS: Overall, 498 patients with 518 primary tumors were analyzed. Of these, 282 (12 of them with synchronous bilateral disease) presented with unknown genetic status at diagnosis and formed the study cohort. The median age at diagnosis was 42.7 years (range, 23.8-77.9). Based on the recent ASTRO guidelines (not including conditionally recommended criteria), 17 of 294 (5.8%) of the carriers had tumors that would be eligible for PBI, including 3 Her2-positive tumors and 5 patients diagnosed between ages 40 and 49 years. Using the ESTRO IORT and the ACROP-ESTRO PBI criteria, 9 of 294 (3%) would be eligible, whereas with the GEC-ESTRO low-risk criteria, 31 of 294 (10.5%) of the carriers would be eligible, and their intermediate risk criteria would increase eligibility for PBI by an additional 8.2% (overall 18.7%). CONCLUSIONS: Using clinical-pathologic criteria published in international guidelines, 3% to 18% of BRCA1/2 PV carriers will have tumors eligible for PBI. Therefore, especially in populations who are at high risk for being BRCA1/2 PV carriers, we recommend adhering to stricter guidelines. In our cohort, ASTRO, ESTRO-IORT, and ESTRO PBI had the lowest probability of identifying BRCA1/2 PV carriers as eligible for PBI.
引用
- Bernstein-Molho R, Abu-Shehada N, Gal-Yam EN, et al. Utility of Clinical-Pathological Parameters for Exclusion of BRCA1/2 Mutation Carriers as Candidates for Partial Breast Irradiation. Pract Radiat Oncol. 2024. PMID: 39218527. doi:10.1016/j.prro.2024.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。